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Furthermore, the authors have used first-generation stiffer
stent grafts intended for treating aneurysms and have gone
through a learning curve for this new technology. Some of
the morbidities and mortalities encountered in the current se-
ries might be reduced/obviated based on our current experi-
ence. For instance, to reduce the possibility of retrograde
type A aortic dissection, we do not balloon dilate the proxi-
mal landing zone and avoid oversizing by more than 15%.
Device sizing is performed based on the normal proximal
aorta after the left common carotid artery. The primary end
points of endovascular interventions are coverage of the
primary entry site, relief of malperfusion (if present), and
stagnation of blood in the false lumen. Intravascular
ultrasonographic scanning has been instrumental in negotia-
tion of the true lumen, accurate measurement of the dimen-
sions of the proximal landing zone, visualization of (large)
secondary entry sites, and evaluation for stagnation of blood
in the false lumen after the obliteration of the primary entry
site. In case of frank ruptures, impending ruptures, uncon-
trolled hypertension, and unrelenting pain, the entire aorta
between the subclavian and celiac arteries is covered. The
availability of a dissection-specific stent graft should im-
prove our outcomes in cases of malperfusion; we would
cover the primary (or large) secondary entry site and use
a bare stent to expand the true lumen throughout the length
of the descending thoracic aorta.
In brief, this series is (to the best of our knowledge) the
largest cohort with the longest follow-up in the literature,
demonstrating favorable early and midterm results for pa-
tients undergoing TEVAR for complicated acute type B aor-
tic dissection. Although long-term durability of TEVAR for
complicated acute type B aortic dissection is yet to be estab-
lished, we conclude that TEVAR is the therapy of choice for
patients with complicated acute type B aortic dissection and
that a paradigm shift is warranted from open surgical treat-
ment to TEVAR in these undesirable surgical candidates.
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Dr D. Craig Miller (Stanford, Calif). Ali, this is very good. We
have to be careful with you here because ‘‘alihi’’ in Hawaiian
means ‘‘chief,’’ and that is close to Ali.
I have no objections whatsoever to your talk this morning, which
is a far cry from what I said last year in New Mexico.
Dr Khoynezhad. I remember that very well. (laughter)
DrMiller. I bet you do, and if you keep coming back every year,
some day we will make you an honorary member, just like Urschel
and Walt Wolfe, so welcome back to the Western Thoracic Asso-
ciation.
I really do appreciate you bringing this material to our attention
because I agree with you wholeheartedly that the best and most life-Cardiovascular Surgery c Volume 138, Number 3 629
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actly these patients: patients with acute type B aortic dissection
with complications, who are dying right under your eyes. It is prob-
ably the application that is being less applied certainly worldwide
and maybe even in the United States. Therefore you have tackled
the toughest patients, and I think you have shown some spectacular
results of which you should be proud.
I really do agree with all your conclusions this year. I have a co-
uple quibbles, and it would not be correct if I did not, right? You
had very tight inclusion/exclusion criteria. I am wondering what
happened and how many there were who were excluded from stent
grafting because they were too sick, could not sign, or did not have
the right anatomy. Do you have any idea what your internal control
group was and how well they did?
Dr Khoynezhad. In regard to open operations?
Dr Miller. Whatever you did.
Dr Khoynezhad. We had 3 patients who required open opera-
tions in the follow-up period. The first patient was operated on at
Creighton University, and 2 patients were operated on at Harbor–
UCLA. In the latter 2 patients, we did not have adequate access
to vessels. The size of the iliac arteries was not adequate for endo-
vascular procedures. Both patients underwent open operations. The
third patient had an emergency operation for a ruptured acute type
B aortic dissection at Creighton University. I try to avoid doing
those operations as much as I can. Having said that, exclusion cri-
teria were severe acidosis, refusal of treatment, no vital signs, any
type A dissections, retro-A dissections, chronic dissection (ie, 14
days after symptoms), and any intramural hematoma or aortic ul-
cers. Any connective tissue disorders were not treated with endo-
vascular treatment either.
Dr Miller. That is fine. I was just getting to the ones who were
too sick and dying. Youwere going to end up doing a warm autopsy
one way or another.
Dr Khoynezhad. There are patients with type A or type B dis-
sections who are not offered open or endovascular procedures.
There are some patients who are too sick. They are severely aci-
dotic, and they decide not to be treated at all, or the patient’s family
declines to do that. I do not have the number for those.
Dr Miller. I am not sure these can truly be called midterm re-
sults. You did not show us in your graft or in the manuscript how
many were remaining at risk at 2, 3, 4, and 5 years and particularly
how many of those had a current CT scan. I will bet you the num-
bers are small, less than a handful, out beyond 2 years, and therefore
it might be more appropriate to term this article ‘‘early results.’’
Dr Khoynezhad. Your point is well taken.
DrMiller.Can you give us some numbers remaining at risk at 2,
3, or 4 years?
Dr Khoynezhad. We started performing endovascular treat-
ment of complicated type B aortic dissection at Harbor–UCLA in
1999 after the initial publication from the Stanford group. I think
we have 20 patients remaining at risk at 1 year, 17 at 2 years, 13
at 3 years, 10 at 4 years, 6 at 5 years, and 2 at 6 years.
DrMiller. That is the safe way.We did that the same in our 2005
paper presented in Victoria, which Dr Cohn hopefully will be pub-
lishing soon in the Journal. (laughter) We had 8 patients at 3 years
and 6 patients at 5 years, and you just cannot say anything with such
a small number of patients out at the end of the curves.
Dr Khoynezhad. Absolutely.630 The Journal of Thoracic and Cardiovascular SuDr Miller. A word of caution. In the ruptures you want to cover
the entire descending thoracic aorta, and I understand why because
you have no idea where they are ruptured, but you only have 4 rup-
tures. If you do that in enough patients, you are going to pay a price,
and the price can be paraplegia. I think we should be cautious. It
reminds me of Frank Criado, a vascular surgeon where Ali got
his training at Torrance, saying to cover it all with impunity. That
does not work out in the patient’s best interest all the time. I would
have to disagree with you there, even though you are flying blind.
You do not know where the actual leak is.
I also have an affirmation. You make 2 pleas in your manuscript.
You say that we have to categorize these patients strictly. I could
not agree more because there is a lot of fuzziness in how these pa-
tients are presented. Second, we have to have uniform standardized
outcome-reporting guidelines. It was very heartwarming to me that
you are using the Stanford treatment failure definition, which is an
overestimate, very comprehensive and too high, but at least it will
be a level playing field. We can apply it from center to center and
make these comparisons in a more meaningful fashion.
Your 82% freedom from treatment failure at 5 years is spectac-
ularly good. Our number was 67% at 5 years.
There are members in the audience who might say your 30% en-
doleaks is bad, and this represents a failure of therapy. That is not at
all correct. These are acute dissections. Our goal is not to get all the
blood flow out of the false lumen. Our goal is to save lives, and that
means to pop open the true lumen, improve the malperfusion, re-
suscitate the patient, and then maybe deal with the persistently pat-
ent false lumen another way when they are in much better
condition. Therefore I do not interpret that as failure in this context,
and I applaud you for pointing that out to the readers.
DrKhoynezhad. I think endovascular treatment for complicated
type B aortic dissection might not be curative for many patients, but
it saves lives in the acute phase, and we always have options to treat
patients with open or endovascular means in the future.
DrMiller. The definition should be applied across the board, ab-
solutely. It is the only way to be fair.
Finally, I applaud what you are doing in Omaha at the University
of Nebraska. You are a cardiothoracic surgeon. You did your endo-
vascular training with peripheral vascular surgeons. That represents
a failure of our CT training structure in this country right now.
Hopefully it will improve in the future, but you are outgrowing
those bad habits you might have learned in Torrance, and you are
doing what is best for the patient in Omaha. Congratulations.
Dr Royce Calhoun (Sacramento, Calif). Ali, I enjoyed your
talk as well. As you know, we stent a lot of traumatic patients,
which I think actually is another subset that benefits from this
technology, although Dr Miller, I am sure, will take some issue
with that. Nonetheless, we see a lot of these patients too, and
we have not been as aggressive stenting them. I think the whole
pain and uncontrolled hypertension thing is such a vague sur-
geon-dependent judgment. In at least the ones that we deal
with, and we deal with probably 20 to 30 of these a year, that re-
ally represents—First of all, they are mostly not complicated.
They are mostly uncomplicated once we get their blood pressure
down. Of the ones that are complicated, usually it is sort of vague
pain, waxing and waning, and hypertension. Of your group, and I
realize most of this probably represents Harbor’s data, do you
know how many of those were truly a sort of malperfusion orrgery c September 2009
Khoynezhad et al Acquired Cardiovascular Diseasesomething where you really had to act versus a judgment about
blood pressure management or something like that?
Dr Khoynezhad. Fifteen patients had malperfusion; 8 had
malperfusion of the lower extremities, and 7 had visceral/renal
malperfusion. As you mentioned, uncontrolled hypertension or
pain is a soft call for this procedure. This was the case in 6
patients. That is one of the points in this article, if Dr Cohn agrees
to publish it. (laughter) The point is basically that we have to
define maximal medical therapy. At my institution, I have estab-
lished a protocol: 3 parenteral antihypertensive medications haveThe Journal of Thoracic and Cto be initiated before we call that case a failure of medical treat-
ment. This has not been addressed in a majority of articles that
I see in the literature currently on complicated acute type B dis-
sections. Having said that, operating on patients with unrelenting
pain or incontrollable hypertension has been the standard of care
for open surgical repair. Therefore it is fair to treat those patients
also endovascularly. These patients who continue to have pain are
operated on in aortic centers of excellence, such as the one in
Houston with Dr Safi, with whom I have had the privilege and
pleasure to work early in my career.ardiovascular Surgery c Volume 138, Number 3 631
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